Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Therapeutic Advances in Neurological Disorders|April 29, 2017
Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosisJana Lizrova Preiningerova, Marta Vachova
Journal of Neural Transmission (Vienna, Austria : 1996)|May 18, 2019
Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?Klara Novotna, Jan Rusz, Eva Kubala Havrdova, et al.
European Neurology|August 8, 2016
Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)Klara Novotna, Lukas Sobisek, Dana Horakova, et al.
Journal of Neuroengineering and Rehabilitation|April 19, 2015
Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5)Jana Lizrova Preiningerova, Klara Novotna, Jan Rusz, et al.
Plos One|February 24, 2023
Is retina affected in Huntington's disease? Is optical coherence tomography a good biomarker?Pavel Dusek, Ales Kopal, Michaela Brichova, et al.
Neuropsychiatric Disease and Treatment|September 21, 2018
Do eyes with and without optic neuritis in multiple sclerosis age equally?Jana Lizrova Preiningerova, Anna Grishko, Lukas Sobisek, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 29, 2016
The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?Daan Ja Crommelin, Karl Broich, Chris Holloway, et al.
Biomolecules|March 25, 2022
Multiple Sclerosis and MicrobiomeJana Lizrova Preiningerova, Zuzana Jiraskova Zakostelska, Adhish Srinivasan, et al.
Journal of the Neurological Sciences|April 9, 2018
Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patientsLucie Kadrnozkova, Manuela Vaneckova, Lukas Sobisek, et al.
Frontiers in Neurology|August 27, 2019
Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple SclerosisMichaela Andelova, Tomas Uher, Jan Krasensky, et al.
Pageof 3